Key facts
- Avana Health’s last known valuation is $28.9M (Jan 2026).
- It has raised $5.9M across 1 recorded rounds; the latest was Seed Round ($2.8M) in Sep 2025.
- Notable investors include Keyhorse Capital, Bioventure Partners, Commonwealth Seed Capital, Michael Heinrich, Pointe Angels — 7 tracked in total.
- Avana Health has filed 3 Form Ds with the SEC since 2022, most recently Dec 2025 ($2.8M sold to 29 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Avana Health
Funding rounds
1 roundsAbout Avana Health
Developer of uterine-focused medical interventions designed for the management of abnormal uterine bleeding and postpartum hemorrhage. The company's platform incorporates device-based and procedural approaches under clinical evaluation, having features such as usage across diverse care settings, compatibility with existing gynecologic workflows, attention to safety and accessibility constraints, and applicability across a wide reproductive age range, enabling healthcare providers to address significant unmet needs in uterine health with options that aim to reduce treatment complexity and broaden global availability.
- Sector
- Healthcare
- HQ
- Lexington, KY, United States
- Founded
- 2021
- Employees
- 10
- Website
- avana.health/
- Ownership
- Privately Held (backing)
Avana Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Avana Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Avana Health in its N-PORT filings yet. We sweep new filings monthly.